Clinical trials: Contraceptive, Oral, Hormonal
Contraceptive Usage, Overweight or Obesity
A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity
Approximately 15 million women of reproductive age women in the United States have overweight or obesity and use the combined estrogen and progestin oral contraceptive pill (COC).
- Conditions
- Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior
- Trial name
- NCT05061472
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Contraception
A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods
This study will assess the continuation rates among women using oral contraceptive pills, Depo-Provera and Ortho Evra following a first trimester abortion.
- Trial name
- NCT00253019
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Emory University
Tubal Patency
HSG and Tubal Patency Study
The investigators' research group is working to develop a highly effective, low cost non-surgical method of permanent contraception for women.
- Trial name
- NCT02146248
- Testing
- combined oral contraceptive, DepoProvera
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Jeffrey Jensen
Contraception
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
- Trial name
- NCT05264506
- Testing
- NOMAC-E2 COC
- Where
- 103 sites in United States
- Volunteers
- 3,055 people
- Sponsor
- Organon and Co
Contraception
Impact of Combined Hormonal Contraceptives on UPA
The purpose of this research study is to determine if taking a birth control pill effects how well an emergency contraceptive pill called Ulipristal acetate (UPA) works.
- Trial name
- NCT02577601
- Testing
- Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Contraception
Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study
Women currently using or starting a combined oral contraceptive will be offered study enrollment. Study subjects will have a Nexplanon placed and followed for 6 months to evaluate if they continue the COC, continue the implant…
- Trial name
- NexTOC (NCT02852265)
- Testing
- Etonogestrel contraceptive implant
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Cystitis, Interstitial, Dysmenorrhea
Chronic Pain Risk Associated With Menstrual Period Pain
The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic…
- Conditions
- Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain
- Trial name
- CRAMPP (NCT02214550)
- Testing
- cyclic microgestin 1/20, continuous microgestin 1/20
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Contraceptive Usage, Vaginal Epithelial Disruption
Hormonal Contraception and Vaginal Health
The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina.
- Trial name
- NCT00612508
- Testing
- Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Contraception
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
- Trial name
- NCT02269241
- Testing
- LF111 (drospirenone)
- Where
- 37 sites in United States
- Volunteers
- 1,552 people, healthy volunteers welcome
- Sponsor
- Laboratories Leon Farma, S.A.